NASDAQ
1.28USD
+0.04 (+3.23%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
434.1M
P/E
—
EPS
—
Beta
2.20
52W range
0.96-2.725
Day range
1.26–1.30
Open
1.26
Prev close
1.24
Volume
4.5M
Avg volume
7.5M
Dividend
0.00
IPO
2014-12-03
https://www.marketbeat.com/instant-alerts/ocugen-eyes-3-retinal-gene-therapy-filings-as-late-stage-pipeline-advances-2026-07-10/ · 7/11/2026+0.80
https://247wallst.com/investing/2026/07/02/cramer-to-a-23-year-old-buy-it-but-it-might-take-a-lifetime-to-make-money/ · 7/2/2026+0.60
https://www.zacks.com/stock/news/2931731/ocugen-s-gene-agnostic-eye-therapies-could-reshape-late-stage-care?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|zer_report_insights-2931731 · 6/3/2026+0.80
https://www.zacks.com/stock/news/2902907/meiragtx-mgtx-soars-6-8-is-further-upside-left-in-the-stock · 4/20/2026+0.20
https://www.zacks.com/stock/news/2878576/ocugen-ocgn-reports-q4-loss-lags-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2878576 · 3/4/2026
https://247wallst.com/investing/2026/01/17/is-apellis-pharmaceuticals-fda-win-just-the-beginning/ · 1/17/2026+0.80
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
